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Abstract
This review summarizes evidence on the smoking/lung cancer relationship, based on the 
author's 50 years’ experience. It starts by illustrating variations in national rates by time 
and sex. It then demonstrates that the relationship of smoking to overall lung cancer risk 
is strong, consistently seen and dose‐related with amount smoked, duration, age of start 
and time of quitting. Relative risks vary markedly by country, but little by sex, age, race, 
occupation, genetics and other factors. Though precisely estimating the smoking risk is 
difficult, the relationship is clearly causal, not explained by bias or confounding. The risk 
from smoking is reduced in lower tar filter cigarettes, and essentially independent of 
mentholation and type of curing. Lung cancer risk is not increased by smokeless tobacco 
use. The relative risk is much greater for squamous/small‐cell carcinoma than for adeno/
large‐cell carcinoma. The argument that the increasing ratio of squamous to adenocarci‐
noma results from changes in cigarettes is shown to be weak, the increase also being seen 
in never smokers, starting before filters were introduced, and associated with diagnostic 
changes. Most of the weak association of lung cancer with passive smoking is explicable 
by confounding and by misclassification of some ever smokers as never smokers.
Keywords: smoking, lung cancer, trends, dose response, quitting smoking, 
confounding, bias, cigarettes, tar reduction, compensation, mentholation, flue‐cured, 
blended, histological type, passive smoking
1. Introduction
While, at the beginning of the twentieth century, lung cancer was a rare disease, it was diag‐
nosed progressively more often over the next 50 years, and various suggestions were made 
during this period that cigarette smoking might be the cause, deriving mainly from the simple 
fact that the incidence and cigarette consumption were increasing concomitantly [1]. Although 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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earlier case‐control studies had been conducted in Germany [2, 3], it was not until studies in 
the UK [4] and in the USA [5] published in the 1950s that serious attention was given to the 
possibility that smoking might cause lung cancer. Following additional evidence from a num‐
ber of large prospective studies, the US Surgeon General concluded [6] that ‘cigarette smoking 
is a cause of lung cancer in men, and a suspected cause of lung cancer in women’, and later 
reports [7–9] have confirmed and extended the conclusions.
Following a section which concerns trends in lung cancer rates, this review summarizes the 
evidence on a number of aspects of the relationship of smoking with lung cancer, and also con‐
siders the evidence on environmental tobacco smoke (ETS) or ‘passive smoking’. In general, 
less attention is given to those aspects that are well‐known and non‐contentious, while deal‐
ing more fully with areas where the evidence is more open to interpretation. Concentration 
also tends to be in areas where the author and his colleagues have been involved in detailed 
reviews of the evidence. As the author has some 50 years of experience, this covers quite a 
wide range of topics, though not all.
2. Trends in lung cancer rates
Figure 1 shows trends in lung cancer rates in eight countries over the period 1946–2010. They 
are presented separately for males and females and for age 15+, weighted according to the 
age distribution of the European standard population. As can be seen, rates in males always 
substantially exceed rates in females. While in each country rates in males have risen to a peak 
and then declined, rates of females have tended to rise over the whole period, though there is 
evidence of flattening out in some countries. The differing trends in the two sexes are consis‐
tent with differing trends in the take up of smoking, which can be clearly seen in the detailed 
data presented in International Smoking Statistics [10].
For both sexes, there is striking variation by country in the trends seen. Points to note are the 
relatively low rates in Sweden and in Japan, and the rapidly accelerating rates in Hungary, 
so that in males, rates are now almost double those elsewhere. It is interesting that the lung 
cancer rates in Canada and the USA are so similar, given the type of tobacco predominantly 
used in Canada is made only from flue‐cured tobacco, while American cigarettes are blended, 
a topic discussed further in Section 3.5.
Trends in the UK are markedly different from those in other countries, particularly in males. 
In the 1950s, rates in males were much higher than in other countries, but following a much 
earlier and steeper decline than elsewhere, are now below those in all countries except Japan 
and Sweden. In 1998, Lee and Forey [11] attempted to determine whether the trends could 
be fully explained by trends in cigarette consumption, concluding that they could not, with 
factors other than cigarette smoking contributing importantly to risk. A contributor to the 
declining trend may have been the introduction of the Clean Air Act in the UK in 1956.
The trends in the UK are very different from those in the USA. Thus, UK rates, once much 
higher than in the USA, are now lower in both sexes. To some extent, this may have coloured 
differing national opinions on the benefits (or otherwise) of changes from high tar plain 
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cigarettes to low‐tar filtered cigarettes. In 2003, Lee and Forey [12] looked in detail at the 
question as to why the trends in the US and UK are so different. Their analyses took into 
account detailed data on trends in the age of starting and stopping smoking, amount smoked 
Figure 1. Lung cancer mortality rates by country and period.
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per smoker and tar levels, and demonstrated clearly that the differing trends in lung cancer 
rates could not be explained by these factors. They concluded that the explanation must lie 
in changes over time in aspects of smoking not considered in the analyses and/or exposure 
to risk factors other than smoking. Evidence relating to a number of possible such smoking 
variables or other risk factors was considered, but no clear explanation of the differing trends 
could be found. Lee and Forey [12] also criticised views expressed in NCI Monograph 13 [13], 
in particular that tar reduction has been ineffective in lowering lung cancer risk, and that 
trends in US lung cancer rates fit in well with trends in smoking habits.
3. Relationship of smoking to overall lung cancer risk
In order to describe the main characteristics of the relationship, this section leans heavily on 
a recently published systematic review with meta‐analysis by Lee et al. [14]. This involved all 
epidemiological studies published before 2000 which included at least 100 lung cancer cases, 
and which provided relevant information on risks associated with smoking. The meta‐ analyses 
involved almost 300 studies, far more than in any other published meta‐analysis.
3.1. Dose‐related increase in risk in current and former smokers
Although the relative risk (RR) estimates vary considerably between studies, the evidence 
of an association is extremely clear from the meta‐analyses [14], with overall random‐effects 
relative risk estimates of 5.50 (95% confidence interval [CI] 5.07–5.96) for ever smokers, 
8.43 (7.63–9.31) for current smokers and 4.30 (3.93–4.71) for ex‐smokers, these RRs all being 
expressed relative to those who have never smoked. Although the individual RR estimates 
are variable in magnitude, they are highly consistent in direction. Thus, of 195 sex‐specific RR 
estimates for current smoking, every single one is greater than 1.0, and all but seven are indi‐
vidually statistically significant at p < 0.05, with as many as 27 of the RRs exceeding 20. These 
estimates are for smoking of any product or for cigarettes if results for any product were not 
available. Estimates for cigarette only smokers were less commonly available but were some‐
what higher, with a combined estimate of 8.95 (7.76–10.33) for current smokers.
That there is a tendency for the RR to increase with number of cigarettes smoked per day is 
abundantly clear. Because studies vary in the groupings used to categorize amount smoked, 
analyses were included in the systematic review [14] comparing ever smoking RRs for three 
groups: ‘about 5 cigs/day’ (the category for which results provided includes 5 but not 20 cigs/
day), ‘about 20 cigs/day’ (includes 20 but not 5 or 45 cigs/day), and ‘about 45 cigs/day’ 
(includes 45 but not 20 cigs/day). The RRs increased steadily with increasing amount smoked, 
being 3.49 (95% CI 3.13–3.89), 7.33 (6.29–8.54) and 13.69 (11.80–15.89) for the three groups.
Later Fry et al. [15], based on model‐fitting techniques, successfully fitted the linear with 
baseline model  log 
e
  RR = 0.833   log 
e
   (1 + 0.81c ) to 97 independent data blocks, where c is cigarettes 
smoked per day. This model predicted quite a linear relationship between c and RR, with the 
RR estimated as 3.86, 6.30, 10.71, 14.77, 18.62 and 22.31 for, respectively, 5, 10, 20, 30, 40 and 
50 cigs/day (see Figure 2).
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Figure 2. Dose‐response relationships for current smoking fitted to 97, 35 and 27 independent data blocks for amount 
smoked, duration of smoking and age of starting to smoke.
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For years smoked, the shape of the dose response was best fitted by a power model  log 
e
  RR = 0.792  
(y / 10 ) 0.74 , where y is years smoked. When applied to 35 data sets, this predicted RRs of 2.21, 3.75, 
5.96, 9.11 and 13.54 for, respectively, 10, 20, 30, 40 and 50 years smoked (Figure 2). Model‐fit‐
ting techniques were also applied to data by age of starting to smoke, the best model being 
log 
e
  RR = 0.176   (7 − a / 10 ) 1.44 , where a is age of start. Here, based on 27 data sets, the RRs declined 
sharply with increasing age of start, being 8.94, 7.80, 6.83, 5.99, 4.66 and 3.66 for, respectively, 
12.5, 15, 17.5, 20, 25 and 30 years (Figure 2).
Although there is uncertainty as to the actual shape of the true dose‐relationship, and mis‐
classification of smoking status and dose may bias the fitted relationships to some extent, it is 
abundantly clear that risk of lung cancer increases markedly with increasing dose, whether 
quantified by increased daily amount smoked, increased duration of smoking, or earlier age 
of starting to smoke.
It is also clear that risk declines, relative to continuing smokers, in those who quit smoking. 
This is evident, not only from the lower RRs in ex‐smokers than in current smokers noted 
above, but also from those studies that report results by time quit. In a review of studies 
published in the 1900s [14] it was estimated that, compared to current smokers, those who 
had quit for ‘about 12 years’ (the category for which results are provided includes 12 but not 
7 years), ‘about 7 years’ (includes 7 but not 3 or 12 years), and ‘about 3 years’ (includes 3 but 
not 7 years) had, respectively, RRs of 0.28 (0.24–0.32), 0.57 (0.50–0.64) and 0.95 (0.84–1.08). 
The lack of any clear reduction in the short‐term quitters is considered to be due to ‘reverse 
causation’ with some smokers quitting due to incipient disease.
A later paper [16], investigated whether the decline in RR of lung cancer following quitting 
(expressed relative to never smokers) could be adequately fitted by a simple, negative expo‐
nential, model. In this model, the excess relative risk ER (= RR – 1) following t years of quitting 
was estimated by multiplying the ER for a continuing smoker by the factor  exp(−  t   log e  2 _____H  ) , where 
H is the estimated half‐life. Thus, for example, if H is 10 years, and the RR for a continuing 
smoker is 11 (ER = 10), the RR for a quitter will be 6 after 10 years of quitting (the ER of 10 being 
halved to 5), 3.5 after 20 years, and 2.25 after 30 years, and will still be doubled after 35 years. 
Based on 106 independent data sets from 85 studies, published up to 2011, it was found that if 
reverse causation was ignored, the model fit was poor, but the fit was much improved if reverse 
causation was allowed for, either by ignoring short‐term quitters, or by considering them to be 
smokers. For the best‐fitting analysis (ignoring short‐term quitters), H was estimated as 9.93 
(95% 9.31–10.60), but varied by sex (females 7.92, males 10.71) and age (increasing from 6.98 for 
age <50 years to 12.99 for age 70+ years). It was concluded that the model adequately described 
the decline in ER, although precise estimates of H may be biased by misclassification of smok‐
ing status and failure to update smoking habits during follow‐up in long‐term prospective 
studies. The large value of H illustrates clearly the persistent effects of smoking.
As shown subsequently [17], the negative exponential model can quite simply be adapted to 
predict risk following changes in exposure more generally. The adaptation was shown to sat‐
isfactorily predict results from those (relatively few) studies that have investigated the effect 
of reducing cigarette consumption, and suggests it may be useful for predicting changes in 
risk following switching to a reduced exposure product.
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3.2. Factors affecting risk
The age‐specific absolute risk of lung cancer is known to be related to many factors other 
than smoking. These include alcohol, occupation, air pollution, diet, viruses and genetic 
factors [18].
However, the evidence considered in this section relates not to which factors modify the risk 
of lung cancer, but to which affect the RR associated with smoking.
3.2.1. Sex
There has been considerable discussion about whether smoking increases the risk of lung 
cancer more in women than in men, e.g. [19]. Based on the systematic review of Lee et al. [14], 
there was little evidence of any difference, though RR estimates generally tended to be higher 
for men than for women. This conclusion was supported by additional analyses comparing 
RRs within individual studies using the same definition of exposure and similar levels of 
amount smoked. The slightly higher RRs in men do not necessarily indicate any greater sus‐
ceptibility, as they may reflect increased exposure to occupational carcinogens, differences in 
duration of smoking or increased use of higher tar and plain cigarettes. Note, however, that in 
prospective studies in which smoking habits are determined at baseline, the greater tendency 
of males to quit during follow‐up may tend to understate the male/female ratio. Though it is 
difficult to get a precise answer on the male/female difference, these results appear to agree 
with the conclusion of Bain et al. [20] that ‘women do not appear to have a greater susceptibil‐
ity to lung cancer than men, given equal smoking exposure’.
3.2.2. Age
Though the absolute risk of lung cancer rises steeply with age, both in never and ever smokers, 
it is far less clear whether the RR also does, particularly when the great majority of published 
studies do not give results by age. However, a number of studies considered in the systematic 
review [14] did provide RR estimates for ever or current smoking separately by age, and it 
was possible to carry out meta‐analyses based on the ratio within study of the estimate for 
the oldest age group for which data were available, compared to that for the youngest. While 
the meta‐analysis did show a significantly higher risk in the oldest age group, the estimated 
average ratio (1.17, 95% CI 1.10–1.25) was quite modest. Clearly, any variation in RR by age is 
much smaller than the RR itself.
3.2.3. Location
There is a striking variation between study locations in the estimated RR associated with 
smoking. For current smoking, where the overall RR estimate for the sexes combined from 
meta‐analyses [14], based on 195 estimates, was 8.43 (95% CI 7.63–9.31), the estimate was 
higher than this for studies based in North America (11.68, 10.61–12.85), and markedly lower 
than this for studies in China (2.94, 2.23–3.88), Japan (3.55, 3.05–4.14), and other parts of 
Asia (2.90, 2.04–4.13), with estimates intermediate in the United Kingdom (7.53, 5.40–10.50), 
Scandinavia (8.68, 7.14–10.54) and other parts of Europe (8.65, 5.98–12.51). The pattern of 
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 variation by location is similar if comparisons are based on ever rather than current smok‐
ing. The extent to which these quite clear differences are due to the product smoked, amount 
smoked, genetics or other factors, is a question which deserves further attention.
3.2.4. Time
The systematic review [14] generally showed a tendency for RRs to be lower in studies which 
started a long time ago. Thus, current smoker RR estimates rose continuously from 6.39 (95% 
CI 4.70–8.69) for studies starting before 1960 to 12.81 (8.70–18.85) for studies starting in the 
1990s. Indeed, in the meta‐regression analyses, start year of study and location were the most 
highly significant (p < 0.001) independent predictors of the current smoker RR. There are a 
number of possible reasons for the time trend, including changes in the use of cigarettes rela‐
tive to pipes and cigars, and improvement in the quality of studies. However, the most plau‐
sible reason seems to be changes in patterns of uptake of smoking, with smokers in the earliest 
studies, born around the turn of the nineteenth century, being less likely to have had a lengthy 
smoking career than later‐born smokers in more recent studies. Note that this increase occurs 
despite evidence, discussed in Section 3.4, that cigarettes have become somewhat less harmful 
due to reductions in tar and the switch to filters.
3.2.5. Race
Few studies considered in the systematic review [14] provided comparable RRs for ever 
or current smoking by race, and these results gave no indication that RRs for Whites dif‐
fered systematically from those for Blacks (or non‐Whites). Comparison of risks in Blacks 
and Whites is in any case made difficult by various differences in their smoking character‐
istics [21]. Thus, while in the USA. Blacks are more often current smokers, are less likely to 
quit smoking, smoke higher‐tar cigarettes and have higher cotinine levels, all characteris‐
tics which would predict a higher risk of lung cancer, they are also less likely to have ever 
smoked, have lower daily cigarette consumption, and start smoking later, all characteristics 
predictive of a lower risk.
Other risk factors were not considered in detail in the systematic review [14]. However, refer‐
ence is briefly made below to some of these.
3.2.6. Asbestos and other occupational exposures
It is well‐known that asbestos exposure increases risk of lung cancer, though the increase 
depends materially on the type of asbestos. In an early large study of US insulation 
 workers [22] RRs, compared to men who had never smoked cigarettes and who were unex‐
posed to asbestos, were 5.17 for those exposed only to asbestos, 10.85 for those who had 
ever smoked only, and 53.24 for those exposed to both risk factors. These results, while 
suggesting a multiplicative relationship and an extremely high risk in those with both 
exposures, do not suggest that the smoking RR varies materially by asbestos exposure. 
A meta‐analysis conducted in 2001 [23] involving 23 epidemiological studies confirmed 
that asbestos exposure and smoking have an approximate multiplicative relationship with 
lung cancer risk.
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There are, of course, numerous occupational factors which affect risk of lung cancer. Nearly 
all, such as arsenic, chromium, nickel, chloromethyl ethers and polycyclic aromatic hydrocar‐
bons increase risk, though a reduced risk has been reported for exposure to endotoxins [24]. 
The author is not aware of any occupation known to materially affect the RR associated with 
smoking. As smokers are more likely to work (or have worked) in ‘dirty’ occupations, there 
is a possible confounding effect of occupation. However, numerous epidemiological stud‐
ies have adjusted for occupation (or indicators of it such as social grade) and the systematic 
review [14] found that the RR for smoking was hardly affected at all by the extent of adjust‐
ment for other risk factors.
3.2.7. Genetics and family history
A review by Lee in 1993 [25] considered the limited evidence then available on family his‐
tory, concluding that risk was approximately doubled in those who have a relative with 
lung cancer. The association has been confirmed in a recent pooled analysis [26] of data from 
24  studies, with the RR of lung cancer associated with having a first degree relative with lung 
cancer estimated as 1.51 (1.39–1.63). The RR was somewhat higher for ever smokers (1.55, 
1.42–1.68) than for never smokers (1.25, 1.03–1.52). Similar results were reported in an earlier 
meta‐analysis [27]. From the pooled meta‐analysis results, one can estimate that the RR for 
ever versus never smoking is somewhat lower in those with a family history of lung cancer 
than in those without, by a factor which can be estimated as 1.25/1.55 = 0.81 (95% CI 0.65–1.00), 
a factor which is of considerably smaller magnitude than the RR for ever smoking of 5.50 
(5.07–5.96), noted in Section 3.1.
The demonstration of an association of family history with lung cancer does not necessarily 
prove there is a genetic determinant of lung cancer, as family members may share aspects 
of smoking such as amount smoked, depth of inhalation and type of product smoked, or be 
exposed to common environmental factors other than smoking (e.g. heating and cooking 
practices). In recent years, there have been a very large number of studies aiming at looking 
more directly at how a whole range of genotypes are associated with lung cancer risk or with 
propensity to smoke. The author's impression of the literature is that associations reported 
are often non‐significant and never strong. Even for well‐studied relationships, such as chro‐
mosome 15q25, the evidence [28–31] only suggests that the variants are associated with an 
increased cigarette consumption of about one cigarette per day, and an increased lung cancer 
risk of about 30–50%. Furthermore, evidence obtained on whether the variants differentially 
affect lung cancer risk in never smokers is very limited. There seems to be no evidence that 
RRs associated with smoking are strongly affected by genetic factors.
3.3. Difficulties in the precise estimation of risk from smoking
3.3.1. Inaccuracy of diagnosis of lung cancer
A review in 1994 by Lee [32] demonstrated substantial evidence of disagreement between 
autopsy, clinical and death certificate diagnosis of lung cancer. Even though autopsy does 
not ensure 100% accuracy even if clinical history is taken into account, it offers the possibility 
of substantially improving the level of accuracy of death certificate data, which is affected 
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by fashion and the particular interests and perceptions of certifying doctors. For example, 
knowledge that a person is a smoker affects diagnostic procedures so that lung cancer in 
a non‐smoker is less likely to be detected clinically than in a non‐smoker. The review also 
bemoaned the decline in autopsy rates, noting that advances in clinical diagnostic techniques 
seem not to be compensating for this in reducing inaccuracy.
While in many Western countries, autopsy rates are very low, this is not so in Hungary, 
or other countries in the old Austro‐Hungarian empire. Autopsies were for many years rou‐
tinely carried out there on all patients dying in hospital. A study there [33] showed a substan‐
tial discrepancy between pre‐ and post‐autopsy diagnosis. In that study, 59% (36/61) of lung 
cancer seen at autopsy were not detected pre‐autopsy, while 50% (25.50) of those diagnosed 
pre‐autopsy were not confirmed at autopsy. Accuracy of diagnosis increased with the number 
of diagnostic techniques applied, but was still far from perfect in the absence of necropsy. 
Under‐diagnosis was commoner in non‐smokers and over‐diagnosis commoner in smokers. 
Although improved diagnostic procedures could have increased accuracy of diagnosis, the 
results certainly imply the possibility of considerable bias to the estimated RR for lung cancer 
and smoking.
3.3.2. Inaccuracy in determining smoking habits
In comparing the risk of ever smokers and never smokers, random misclassification of smok‐
ing habits tends to dilute any true association with lung cancer risk. Thus, if the true RR is 
10, and there are 50% ever and 50% never smokers random misclassification of 5% of the 
population into the wrong group would lead to the observed RR being (47.5 × 10 + 2.5 × 1)/
(47.5 × 1 + 2.5 × 10) = 6.59. The major determinant of the bias is misclassification of ever as 
never smokers rather than the reverse. The association would also be diluted, if cases deny 
or understate their smoking, though this would not be relevant in prospective studies, where 
smoking habits are determined before onset of disease. Any tendency for current smokers to 
claim to be ex‐smokers, as might happen in a situation where patients have been advised to 
stop smoking, would tend to increase the RR for ex‐smokers and reduce the RR for current 
smokers. Generally, plausible levels of misclassification of smoking habits cannot explain the 
observed association of smoking with lung cancer.
3.3.3. Confounding factors
In the systematic review of Lee et al. [14] adjustment for age and other factors was found to 
have very little effect on the overall estimate of the RR associated with smoking. The conclu‐
sion of a minimal effect of confounding is consistent with that from an analysis of data from 
the very large US Cancer Prevention Study II [34]. It is in any case clear that the smoking RR is 
too large to be explained by confounding. For an RR which comfortably exceeds 10 for heavy 
smokers to be an artefact of confounding would require there to be another risk factor which 
is both extremely strongly related to lung cancer and to which smokers are very much more 
commonly exposed than non‐smokers. While some rare risk factors (e.g. bis(chloromethyl)
ethyl exposure) increase lung cancer risk very markedly, and smokers and non‐smokers do 
differ in a range of characteristics, no factor (or group of factors) has emerged which can come 
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close to explaining the observed RR for smoking in terms of confounding. Certainly there is 
no good evidence to support early theories by Fisher [35] and Burch [36] that the association 
of smoking with lung cancer might be totally explained by genetic factors. This theory seems, 
in any case, to be refuted by the observation that in smoking‐discordant identical twins, risk 
of lung cancer was much higher in the twin who smoked [37–38].
Confounding is a more relevant issue when considering the dose‐related aspects of smoking. 
As shown in the systematic review [14], adjustment for other aspects of smoking (typically 
including amount smoked) consistently reduces associations of lung cancer risk with age of 
starting to smoke, duration of smoking, years quit and tar level. This is because earlier starters 
and high tar smokers tend to smoke more heavily than do later starters and low‐tar smokers, 
and lighter smokers tend to be more ready to quit smoking.
3.3.4. Publication bias
The tendency for researchers to be more likely to want to publish, and editors more likely to 
accept for publication, studies finding a statistically significant association may cause impor‐
tant bias for some relatively weak associations of exposure to disease [39, 40]. However, the 
association of smoking with lung cancer is too strong and consistently reported for publica‐
tion bias to be a material explanation of the strong relationship.
3.3.5. Recall bias
In case‐control studies, the smoking habits reported by a case may be affected by knowledge 
of the disease, particularly where the disease is widely reported to be caused by smoking. 
However, the fact that smoking RRs are quite similarly elevated in prospective studies (where 
such recall bias is not a possibility, smoking habits being reported before onset of the cancer) 
as in case‐control studies (where it is a theoretical possibility) appears to rule out recall bias as 
an explanation for the observed association.
3.3.6. Assessment of conclusions
While there are a number of factors that affect precise estimation of the risk of lung cancer 
from smoking, it is very clear that smoking is an important determinant of risk. Looking back 
at the Bradford Hill criteria for determining whether an association is due to causation [41] 
the available evidence discussed above clearly demonstrates strength, consistency, tempo‐
rality (with the exposure preceding the disease) and biological gradient (or dose response). 
The relationship also satisfies plausibility, given the numerous known carcinogens in tobacco 
smoke, and coherence, the evidence not conflicting with known facts concerning the natural 
history and biology of lung cancer. There is also experimental evidence, partly in humans 
in relation to the decline of risk following quitting, and partly in animals, with exposure to 
tobacco for having been shown to increase risk of skin cancer in mice and exposure to tobacco 
smoke having been shown to elicit lung tumours in rodents [9]. One could also argue analogy 
with regular inhalation of other pollutants increasing risk of lung cancer. Of the nine Bradford 
Hill criteria, the only one it fails is specificity. Smoking is clearly not a necessary condition 
for lung cancer to arise, inasmuch as there are other causes of lung cancer. Nor is it sufficient, 
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as many smokers do not contract the disease. Though some old dictionary definitions appear 
to equate ‘cause’ to ‘necessary and sufficient cause’, this is not what is meant by saying that 
smoking causes lung cancer.
3.4. Types of product
While in most countries the majority of cigarette smokers smoke manufactured cigarettes, with 
relatively few smokers using hand‐rolled cigarettes, in some countries, e.g. the Netherlands 
and Norway, hand‐rolled smoking is relatively common [10]. The systematic review of stud‐
ies in the 1900s [14] included 20 independent within‐study estimates of the ratio of risk in 
hand‐rolled versus manufactured cigarette smokers, which produced a combined RR esti‐
mate of 1.29 (95% CI 1.12–1.49), based mainly on lung cancers in men. The conclusion of a 
somewhat higher risk for hand‐rolled cigarette smokers is consistent with that in an earlier 
review relating lung cancer to type of cigarette smoked [42].
That systematic review [14] also included results indicating that the RR of lung cancer was 
substantially lower for smokers of pipes and cigars than for cigarette smokers. Thus, for cur‐
rent smoking, while the RRs for cigarette only and for mixed cigarette and pipe/cigar smok‐
ers were, respectively, 9.57 (95% CI 7.90–11.59) and 9.60 (8.37–11.00), they were consistently 
lower for smokers of pipes only (5.20, 3.50–7.73), cigars only (4.67, 3.49–6.25) and smokers of 
pipes and/or cigars only (4.76, 3.44–6.59). Lower risks for smokers of pipes and cigars were 
also evident when results for ex‐smokers or ever smokers were considered. Data on the types 
of cigars or pipes smoked were not considered, but the increased risk was evident in each 
continent. However, it is doubtless true that risk does vary to some extent by the type of pipe 
and cigar smoked.
There has been considerable research into the health risks of smokeless tobacco in Western 
populations, mainly based on data for Sweden, where a type of moist snuff known as snus is 
the dominant product, and for the USA, where chewing tobacco is common, and moist and 
dry snuff are also used [43–45]. The results provide no indication of any increased risk of 
lung cancer associated with smokeless tobacco use. They may help to explain the relatively 
low risk of lung cancer in Sweden (see Figure 1), where snus use is a common alternative to 
cigarette smoking.
3.5. Type of manufactured cigarette
Over the second half of the last century, the characteristics of manufactured cigarettes have 
changed substantially [10]. In the mid‐1950s, cigarettes were typically of the non‐filter plain 
variety with average tar levels exceeding 30 mg/cigarette. By now, nearly all cigarettes smoked 
have filters and average tar levels are around 10 mg/cigarette in many countries. Nicotine 
yields per cigarette have reduced by a similar factor.
An important question is whether these changes, introduced in order to reduce risk, have 
actually done so. Two points are worth making at the outset. The first is that, though the 
observed rise in RR for current smokers over the second half of the last century which was 
noted above would appear to suggest that the risk of cigarettes might have increased, this is 
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not necessarily so, as changes in average duration of smoking by smokers have clearly had a 
major effect, and may mask any effects of the switch to lower tar filter cigarettes.
The second is that there is clear evidence of what is commonly termed ‘compensation’. Thus, 
whereas one might expect smokers switching from cigarettes with a nicotine yield (machine‐
measured under standard smoking conditions) of, say, 2 mg/cigarette, to cigarettes with a 
nicotine yield of 1 mg/cigarette to halve their nicotine uptake, the reduction in measured dose 
is typically much less than this. This may, in theory, be because smokers increase their daily 
consumption or because they change how they smoke the cigarettes, the second possibility 
being more plausible given that consumption per smoker has changed little over the years in 
most countries [10].
Scherer and Lee [46] recently reviewed the available evidence on the extent of compensation, 
based partly on brand‐switching and partly on cross‐sectional studies. Using estimates based 
on nicotine biomarkers, commonly cotinine, they estimated a weighted mean compensation 
index of 0.781 (95% CI 0.720–0.842), where a value of 1 indicates complete and 0 no compensa‐
tion. The index is estimated from a formula in which the biomarker, B, is related to the yield, 
Y, the formula  B =  μ  Y 1−C where  μ is a constant and C is the index. Thus, if C = 1, the biomarker 
is independent of the yield, while if C = 0, the biomarker is directly proportional to it. Using 
their estimated value of C of 0.781 would imply that a 50% reduction in yield would only 
produce a 14% reduction in dose, as assessed by the biomarker. This suggests that any effects 
of a reduction in nicotine yield on lung cancer risk are likely to be much less than would be 
suggested by the reduction in yield.
Various reviews have assessed the evidence on risk associated with the switch to lower tar 
filter cigarettes. In one of the earliest reviews [42], it was calculated, based on 43 sex‐specific 
estimates, that the risk of lung cancer was 36% lower (95% CI 27–44%) in filter than in plain 
cigarettes, and 23% lower (95% CI 27–44%) for lower than higher tar cigarettes. The esti‐
mated reduction, seen in both sexes, equated to 2–3% risk reduction per mg tar per ciga‐
rette. Following publication of a report by the National Cancer Institute [13] claiming that 
the apparent benefits of lower delivery cigarettes may be illusory if RRs are adjusted for daily 
consumption, Lee and Sanders [47] investigated the claim by comparing RRs unadjusted 
and adjusted for consumption. They found clear reductions in risk associated with both fil‐
ter and lower tar cigarette consumption, regardless of adjustment, reductions which were 
evident regardless of sex, study location, time period or study design. Their 2012 systematic 
review [14] also included a number of relevant results, among which were an estimated RR 
of 0.69 (95% CI 0.61–0.78) for only filter versus only plain smoking, and of 1.42 (1.18–1.71) for 
higher versus lower tar smoking.
It should be noted that the evidence considered is limited by the range of tar levels tested 
in any one study being often quite small (as all long‐term smokers have experienced reduc‐
ing tar levels), and also by there being essentially no evidence on risk of ultra‐low (≤3 mg) 
tar cigarettes. Also, there are various other limitations, including difficulties in obtaining 
individual results in a comparable format, inadequate reporting of results, possible unreli‐
ability of the data recorded on cigarette type, and lack of adjustment in some studies for 
potential confounding variables. However, the results clearly suggest that the switch to lower 
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tar filter cigarettes has been beneficial, though the benefit has been substantially reduced by 
compensation.
That cigarette mentholation might increase risk of lung cancer has some plausibility. First, the 
acute respiratory effects of menthol might affect inhalation of cigarette smoke, and secondly, 
in the USA, Black men (who have a very strong preference for mentholated cigarettes) have 
lung cancer rates that are substantially higher than those for White men. However, a system‐
atic review by Lee [21] concluded that the epidemiological evidence is actually consistent 
with mentholation having no effect on the lung carcinogenicity of cigarettes. That review 
identified eight generally good quality studies, all but one conducted in the USA, which gave 
a combined RR estimate for ever versus never use of mentholated cigarettes of 0.93 (95% 
CI 0.84–1.02), with no significant evidence of any effect in males or females, or in Blacks or 
Whites. Noting also that, in the USA, Black women (who also have a very strong menthol 
preference) have lung cancer rates which are no higher than in Whites, the high rates in Black 
men cannot be explained by their greater preference for mentholated cigarettes.
Based on the tobacco they include, most cigarettes sold can be divided into two categories; 
flue‐cured (or 100% Virginia) cigarettes, and blended (or American blended) cigarettes. The 
tobacco in flue‐cured cigarettes is cured over a short period (about a week) at high temper‐
atures, while blended cigarettes are based on three types of tobacco (flue‐cured, Burley or 
Oriental) blended together [48]. Burley and Oriental tobaccos are air‐cured over a period of 
about 6 weeks, the three tobacco types being genetically different. Different countries tend to 
predominantly use the different types of cigarettes. For example Austria, Denmark, Germany 
and the US use mainly blended cigarettes, while Australia, Canada and UK use mainly flue‐
cured cigarettes [10]. Comparing lung cancer risk for smokers of flue‐cured and blended ciga‐
rettes is not straightforward since epidemiological studies are typically conducted in a single 
country where the smokers are likely to all (or virtually all) use one cigarette type or the other. 
An alternative approach tried by Lee et al. [49] was to compare lung cancer risk (for 1971–2000) 
by sex, age and period for those four countries listed above which traditionally use blended 
cigarettes, and those three listed countries which use flue‐cured cigarettes. The comparisons 
were made both unadjusted and adjusted for prevalence of current and former smoking and 
for consumption per smoker. This approach was not particularly sensitive, due to the limited 
number of countries which (a) could both be clearly categorized by type, (b) had relevant data 
available and (c) did not have a large proportion of smokers of products other than cigarettes. 
However, it did not suggest any material effect of cigarette type on risk. Particularly note‐
worthy are the quite similar lung cancer rates and trends in the USA and in Canada shown in 
Figure 1, with one country using blended and the other flue‐cured cigarettes.
4. Differential effect of smoking on histological type of lung cancer
4.1. Classification and diagnosis of histological type
The classification of lung cancer based on its microscopic characteristics, formulated nearly 
100 years ago [50], has changed little in general structure, with the great majority of lung 
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 cancers classified into one of four basic types—squamous cell carcinoma, adenocarcinoma, 
small‐cell carcinoma and large‐cell carcinoma. However, successive WHO classifications 
[51–53] have differed in how tumours should be ascribed to these types, and there are consider‐
able difficulties in ensuring an accurate and consistent diagnosis, with evidence of intra‐ and 
inter‐observer variability of classification [54–56]. Part of the problem lies in the morphologi‐
cal heterogeneity of lung cancers with some tumours, and occasionally even in a single tissue 
block, presenting evidence of more than one type of lung cancer [57]. It is also clear that the 
morphological type of tumour is influenced by its site within the lung and by how the speci‐
men was obtained.
4.2. Variation in relative risk of lung cancer by histological type
In their systematic review of studies published in the twentieth century [14], Lee et al. 
 presented a range of RR estimates, not only for all lung cancer but also for squamous cell 
carcinoma. More limited results are also shown for small‐cell and large‐cell carcinoma. For 
current smoking overall RRs were strikingly higher for small‐cell carcinoma (18.17, 95% CI 
12.92–25.56) and squamous cell carcinoma (16.43, 12.66–21.32) than for adenocarcinoma (4.05, 
3.15–5.22), with that for large‐cell carcinoma (8.56, 5.29–13.86) being intermediate. The same 
pattern was seen for ever smoking.
For all lung cancer types RRs varied substantially by location, being much higher for 
North America than for China, with no clear pattern seen for other regions, some with sparse 
data. Evidence that risk increases with increasing amount smoked and duration of smok‐
ing and earlier age of starting to smoke was seen for both squamous cell carcinoma and 
for adenocarcinoma, though RR estimates were much higher for squamous cell carcinoma. 
Indeed, for squamous cell carcinoma, combined RRs, each based on a substantial number 
of estimates, were of order 30 for heavy smokers (about 45 cigs/day), long‐term smokers 
(about 50 years) and early starting smokers (about age 14 years). RRs for ex‐smokers were 
also substantially higher for squamous cell carcinoma (8.74, 95% CI 6.94–11.01) than for ade‐
nocarcinoma (2.85, 2.20–3.70). In a separate publication [58], based on data from 85 studies 
comparing cancer risks in current smokers, quitters (by time quit) and never smokers, it was 
found that the rate of decline in RR following quitting was somewhat less rapid for adenocar‐
cinoma than for squamous cell carcinoma, where the half‐lives were estimated, respectively, 
as 14.45 (11.92–17.45) and 11.68 (10.22–13.34). The slower decline in risk for adenocarcinoma 
was evident in subgroups by sex, age and other factors.
4.3. Possible explanations for the time shift in the relative frequency of adenocarcinoma 
and squamous cell carcinoma
A shift in the relative frequency of adenocarcinoma to squamous cell carcinoma over time 
has been clearly evident in many countries [59], and in 2014, the US Surgeon General [7] 
argued that the increasing incidence and relative frequency of adenocarcinoma has resulted 
‘from changes in the design and consumption of cigarettes since the 1950s’. The argument 
that the switch from higher tar, plain cigarettes to lower tar, filtered cigarettes is responsible 
for the rise in adenocarcinoma had been made previously [60–62] and supported by various 
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researchers [63, 64]. However, there are a number of reasons which indicate that this conclu‐
sion is, to say the least, over‐simplistic.
One reason for doubting the claim is that the observed shift in the relative frequency of ade‐
nocarcinoma to squamous cell carcinoma began well before the increase in consumption of 
low‐tar filtered cigarettes started [65].
Had there been an adverse effect of low‐tar filter cigarettes on risk of adenocarcinoma, one 
might have expected to see that for adenocarcinoma, the filter versus plain RR would be 
significantly increased. However, this is not the case [14, 42, 47], the systematic review [14] 
giving RRs close to 1, whether comparison was made between only filter and only plain smok‐
ers (0.84, 95% CI 0.66–1.08), ever filter and only plain smokers (0.99, 0.84–1.16) or only filter 
versus ever plain (0.98, 0.80–1.21). In contrast, significantly reduced risks were seen for the 
same three comparisons for squamous cell carcinoma 0.52 (0.40–0.68), 0.55 (0.41–0.74) and 
0.69 (0.57–0.83), respectively. That the switch to lower tar filtered cigarettes has not resulted 
in an increase in risk for adenocarcinoma is also consistent with evidence from more recent 
studies [63, 66, 67]. Note that the reduced RRs for filtered cigarette smoking for squamous cell 
carcinoma suggests that the switch has been beneficial, not adverse, though the magnitude of 
effect is not enough to explain the observed large rise seen in the relative frequency of adeno‐
carcinoma to squamous cell carcinoma.
Although the US Surgeon General [7] dismissed changes in diagnostic procedures as unimport‐
ant, there is quite clear evidence they are relevant, as indicated by three facts. First, schemes for 
classifying histological type of lung cancer have changed over time, notable being the realloca‐
tion of one of the four classes of large‐cell carcinoma in the WHO classification [51] to adenocarci‐
noma in the 1981 classification [52]. Secondly, large studies where diagnoses of histological type 
made some years earlier were reviewed later by pathologists using later classification schemes 
generally report an increase in numbers of adenocarcinoma [68]. Finally, studies using standard 
criteria to review cases collected over a period of at least 10 years found no increase in the propor‐
tion of lung cancers classified as adenocarcinoma [68, 69]. Interestingly one of those  studies [69] 
reported a substantial rise in the rate of bronchioloalveolar carcinoma, which affected smokers 
and non‐smokers alike, and which the authors suggested may have a viral origin.
A huge weakness in the Surgeon General's argument [7] is that it would predict that the shift 
from squamous cell carcinoma to adenocarcinoma would be confined to smokers. Two pieces 
of work clearly indicate that there has been a clear change in never smokers. An analysis in 
2013 [70] indirectly estimated absolute lung cancer mortality rates by smoking habit, time 
period‐ and histological‐type‐based studies published in the twentieth century, coupled with 
WHO mortality data for the same country and period. Thus, while in never smoker rates of 
squamous cell carcinoma per 100,000 per year were estimated to vary little by time period (7.6, 
12.6, 12.7, 10.2 and 11.6 for, respectively, 1930–1960, 1961–1970, 1971–1980, 1981–1990 and 
1991–1999) the corresponding rates for adenocarcinoma increased sharply for the same time 
period, (6.9, 17.0, 18.1, 29.0 and 33.9).
The change in never smokers is illustrated more clearly in a recent publication [68] which 
examined how the proportion of adenocarcinoma in never smokers varied by time, sex and 
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region, based on 219 sex‐ and period‐specific blocks of data drawn from 157 publications. 
Compared to the period 1950–1960, the ratio of adenocarcinoma to squamous cell carcinoma 
was higher by factors of 1.67, 1.97, 2.35 and 3.93 for, respectively, 1970–1979, 1980–1989, 1990–
1999 and 2000 onwards. This publication presents arguments that the time trends could not be 
explained by changes in ETS exposure, or misclassification of ever smokers as never smokers.
While the switch to lower tar filtered cigarettes may have affected the relative frequency of 
adenocarcinoma to squamous cell carcinoma, the epidemiological evidence suggests that this 
is because changes in cigarettes have reduced risk of squamous cell carcinoma, not because 
they have increased risk of adenocarcinoma. The evidence also suggests that the differing 
trends by histological type are due partly to changes in diagnosis and classification and partly 
to other factors that have affected both non‐smokers and smokers. What these factors are 
requires further research.
5. Relationship of ETS exposure to lung cancer risk
As active smoking causes lung cancer, and as ETS contains many of the carcinogens in tobacco 
smoke, one might expect there to be some increased risk from ETS exposure. However, expo‐
sure to smoke constituents from ETS is very much less than exposure from active smoking, 
with studies based on cotinine (the major metabolite of nicotine) suggesting relative exposure 
factors of order 0.06% [71]–0.4% [72]. For particulate matter, a series of studies conducted 
in different countries by Phillips et al., e.g. [73, 74], suggests a lower factor still, of about 
0.005–0.02%. Given that the chemical compositions of ETS and of tobacco smoke are not iden‐
tical, and given doubts about the shape of the dose response at low doses, it is not clear what 
increase in risk one might expect to be associated with ETS exposure. However, two things are 
evident. First, any increase in risk is likely to be quite low, if it exists at all, making it extremely 
difficult to detect reliably using epidemiological methods. Second, any increase in risk is only 
likely to be demonstrable in never smokers or in those with a smoking history that is very 
limited or ceased a long time ago [75].
Since the first publications in the early 1980s [76–79], reports of studies of ETS and lung cancer 
in never smokers have proliferated, and a recent meta‐analysis [80] presented a systematic 
review of 102 studies. Except where noted, the conclusions reached are based on this review.
5.1. Relative risk by source of exposure
The early studies were mainly conducted in women, comparing risk in never smokers mar‐
ried to smokers and in never smokers married to non‐smokers. There were good reasons for 
this: a much larger proportion of women than men had, at that time, never smoked; whether 
a spouse smoked or not could be determined quite reliably; and studies showed that cotinine 
levels in never smokers married to smokers were clearly (about three times) higher than in 
never smokers married to non‐smokers [81]. However, over the years, evidence has been col‐
lected on a wide range of markers of ETS exposure, with some studies collecting extremely 
detailed histories of exposure.
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Based on the meta‐analyses [80] using random‐effects estimates to account for the substan‐
tial between‐study heterogeneity, significant (p < 0.05) positive associations were found 
with all the most commonly studied indices of exposure. The estimated RRs were 1.22 (95% 
CI 1.14–1.31) for smoking by the husband (or nearest equivalent exposure for which results 
were available), 1.14 (1.01–1.29) for smoking by the wife, 1.22 (1.15–1.30) for workplace expo‐
sure, 1.15 (1.02–1.29) for childhood exposure and 1.31 (1.10–1.45) for total exposure, each RR 
being based on a substantial number of studies. Based on very much less evidence no signifi‐
cant association was seen with ETS exposure in travel or in social situations, and interestingly 
a significant negative relationship was seen for ETS exposure in childhood specifically from 
the parents, with the relative risk of 0.78 (0.64–0.94). The RR for smoking by the husband 
could also be expressed as 1.10 (1.07–1.14) per 10 cigarettes smoked, using available dose‐
response data.
5.2. Factors affecting relative risk estimates
In order to study heterogeneity further the review [80] looked at the 119 relative risk estimates 
for smoking by the husband or wife (or nearest equivalent), where the overall estimate was 
1.21 (95% CI 1.14–1.29), and found evidence that the largest relative risks were seen in small 
studies of fewer than 50 cases (1.47, 1.15–1.88), in the earliest studies, published before 1990 
(1.38, 1.24–1.54), and in studies that did not adjust for age (1.42, 1.18–1.71). However, with one 
minor exception, some increase was seen in all the subgroups studied (which included loca‐
tion and study design).
There was also evidence of an increase, for spousal smoking, both for squamous cell carci‐
noma and adenocarcinoma.
5.3. Difficulties in interpreting the association
Whereas the RR for active smoking is large and cannot plausibly be attributed to bias or con‐
founding, that for ETS exposure is substantially smaller, making a causal conclusion difficult 
to establish with any certainty. In the recent review [80], various potential sources of bias were 
discussed. Some sources were dismissed as being unlikely to be very relevant. These include 
publication bias, because large studies, which contribute most to the overall estimates, seem 
likely to publish their findings regardless of the results; recall bias, because the overall esti‐
mates varied little according to whether the study design was prospective (where recall bias 
is not an issue) or case‐control (where it is), or according to diagnostic inaccuracy, because 
estimates were quite similar for studies that did or did not require full histological confir‐
mation. Bias due to the reference group (never smokers married to never smokers) actually 
having some ETS exposure was considered, with comments made in the review [80] on the 
‘background correction’ of Hackshaw et al. [81] aimed at converting an RR for marriage to 
a smoker to an RR expressed relative to never smokers with no ETS exposure at all. It was 
noted that this background correction only makes sense when the original association, with 
marriage to a smoker, derives from a causal relationship, and only applies to the RRs for mar‐
riage to a smoker, and does not affect the estimates of the increase in risk for amount smoked 
by the husband.
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However, the review [80] did demonstrate clearly that confounding and misclassification of 
active smoking were extremely important issues which had a profound effect on the interpre‐
tation of the observed association of ETS exposure with lung cancer risk. The evidence that 
confounding may be a material issue derived from observations made some years ago [82, 83] 
strongly suggesting that, for a wide range of risk factors, exposure to the risk factor is higher 
in non‐smokers exposed to ETS than in those not exposed to ETS. For some of these risk 
factors, available data are inadequate to provide any sort of reliable quantitative estimate 
of their relationship to lung cancer risk in non‐smokers, but for four, increased dietary fat 
consumption, reduced fruit consumption, reduced vegetable consumption and fewer years of 
education, it was established that they were associated both with increased lung cancer risk 
and with increased ETS exposure in non‐smokers. The review [80] found that adjustment for 
confounding reduced the RR for husband smoking from 1.219 (95% CI 1.138–1.305) to 1.139 
(1.062–1.221), and for 10 cigs/day smoked by the husband from 1.102 (1.065–1.140) to 1.062 
(1.027–1.099). Taking into account that adjustment is only for some risk factors, this illustrates 
the considerable potential for bias.
Bias from misclassification of active smoking arises partly because some current or former 
smokers are known to deny having smoked, so being wrongly described as never smokers 
[84, 85], and partly as smokers tend to marry smokers [75, 81]. Taken together, these two 
 tendencies, if ignored, will bias the observed association of smoking by the husband to lung 
cancer risk in never smokers [81, 86, 87]. Based on what were regarded as reasonable esti‐
mates of the extent to which misclassification occurs and of the magnitude of the concordance 
between spouse's smoking habits it was found that correction for misclassification of smoking 
habits further reduced the confounder‐adjusted estimates to 1.077 (0.999–1.162) for husband 
smoking and to 1.032 (0.994–1.071) for 10 cigs/day.
Given that adjustment for confounding and misclassification correction substantially weakens 
the association of lung cancer with the index of ETS exposure that is most usually considered 
(smoking by the husband) and renders it non‐significant, and given that these adjustments 
and corrections may be incomplete, it seems that one cannot reliably conclude that any true 
causal effect of ETS exposure on lung cancer risk has been demonstrated. If there were any 
true relationship, it would certainly be much weaker than suggested by meta‐analyses that do 
not adjust for confounding and misclassification.
6. Final comments
Some of the conclusions expressed here may disagree with those of other researchers. These 
include the risks of smoking being similar in men and women; the modest benefits of the 
switch to lower tar filter cigarettes; the inaccuracy of many diagnoses of lung cancer; the 
lack of evidence that cigarettes made from blended tobaccos (as used in the USA) are more 
harmful than cigarettes made from flue‐cured tobacco (as used in the UK); the rise in the 
relative frequency of adenocarcinoma to squamous cell carcinoma (seen in never smokers, 
and affected by changes in diagnosis and classification) not being explained by changes in 
cigarettes; and the observed association of ETS exposure to lung cancer risk being to a large 
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extent due to bias and confounding. However, it should be emphasised that all the conclu‐
sions arrived at from a detailed and careful study of the evidence, including as far as possible 
all relevant papers that have been published on these subjects, with in some cases reference 
back to the raw data.
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